Treatment of Type 2 Diabetes in Advanced Chronic Kidney Disease (eGFR < 30 mL/min/1.73 m²)
Glycemic management in adults with type 2 diabetes requires a distinct approach when advanced chronic kidney disease is present and the estimated glomerular filtration rate has fallen below 30 mL/min/1.73 m². Agent selection must account for both glycemic safety and cardiovascular risk in this population, including those receiving dialysis.
Clinical scenario: Adult with type 2 diabetes and advanced chronic kidney disease — estimated glomerular filtration rate below 30 mL/min/1.73 m², including individuals on dialysis.
Treatment approach (partial overview)
In this setting, a particular class of glucose-lowering therapy is preferred — it carries a lower risk of hypoglycemia and offers cardiovascular benefit. Importantly, not all agents within this class are appropriate here; those cleared by the kidneys must be avoided. Individuals on dialysis may still be candidates for certain therapies within this class. The complete evidence-based protocol — including which agents are indicated, which must be avoided, and the rationale — is available via the link below.
References
DOI: 10.2337/dc26-S009
- In adults with type 2 diabetes and advanced CKD (eGFR <30 mL/min/1.73 m²), a GLP-1 RA is preferred for glycemic management due to lower risk of hypoglycemia and for cardiovascular event reduction.
- Individuals on dialysis can be safely initiated or continued on GLP-1–based therapy (that is not dependent on kidney clearance) to reduce cardiovascular risk and mortality.
- The GLP-1 RAs lixisenatide and exenatide, which require the kidneys for elimination, should be avoided in individuals with eGFR ≤30 mL/min/1.73 m² or with creatinine clearance ≤30 mL/min, respectively.
View source ↗